Rigel Pharmaceuticals Inc (NASDAQ: RIGL)

Rigel Pharmaceuticals Inc is a biotechnology company focused on developing and delivering novel therapies for patients with hematologic disorders and cancer. The company concentrates on targeting signaling pathways that are central to disease mechanisms. Its approved product portfolio includes TAVALISSE for chronic immune thrombocytopenia REZLIDHIA for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation and GAVRETO for metastatic RET fusion positive non small cell lung cancer and certain thyroid cancers. Rigel also advances a pipeline of investigational candidates such as the dual interleukin receptor associated kinase 1 and 4 inhibitor R289 for lower risk myelodysplastic syndrome and continues to explore additional indications for its existing assets through internal research and collaborations with academic institutions and other pharmaceutical firms.

Rigel generates revenue primarily from the sale of its approved products TAVALISSE REZLIDHIA and GAVRETO to patients through prescription channels. In 2025 net product sales were $158.8 million for TAVALISSE $31.0 million for REZLIDHIA and $42.1 million for GAVRETO. In addition to product sales the company earns income from collaboration and licensing agreements. For example Rigel recognized contract revenue from its partnership with Lilly after opting out of further cost sharing for the osteoclast inhibitor program. The company also receives milestone payments and royalties from partners such as Kissei and Dr. Reddy’s for the commercialization of its products in territories outside the United States. These streams complement product sales and contribute to overall financial performance.

Rigel operates in a highly competitive biotechnology and pharmaceutical landscape where it faces established therapies and emerging rivals. For TAVALISSE the main competitors include corticosteroid treatments thrombopoietin receptor agonists such as romiplostim and eltrombopag and the newly approved drug wayrilz. The company’s advantage lies in its distinct mechanism of action as a spleen tyrosine kinase inhibitor which offers an alternative for patients who have failed standard therapies. In the relapsed or refractory acute myeloid leukemia space REZLIDHIA competes with ivosidenib but differentiates itself through a favorable safety profile and durable responses in heavily pretreated patients. For GAVRETO the primary competitor is selpercatinib however Rigel benefits from orphan drug exclusivity and a once daily oral dosing regimen that may improve adherence. Across all programs Rigel leverages its expertise in kinase inhibition intellectual property protection and strategic collaborations to maintain a defensible position.

Rigel’s customers are principally hematologists oncologists and other healthcare professionals who prescribe its therapies to adult and pediatric patients with specific indications. The company distributes its products through third party wholesale distributors specialty pharmacies and group purchasing organizations before they reach the point of care. In the United States Rigel supports access through its patient assistance program Rigel OneCare which provides copay assistance to commercially insured patients and free product to qualifying uninsured or underinsured individuals. Internationally the company relies on partners such as Kissei in Japan Korea and Taiwan Dr. Reddy’s in Latin America and other regions and Medison in Canada and Israel to commercialize its products. While specific corporate customer names are not disclosed in the filing the base comprises medical institutions clinics and pharmacies that serve the patient populations targeted by Rigel’s therapies.